Placebo effects are common in medicine. Randomised clinical trials help us to understand their magnitude in different therapies. There are particular problems with placebo effects in allergen immunotherapy (AIT) as it is difficult to blind the active treatment and the endpoints are largely subjective. This may explain why large placebo effects are often found in AIT trials. Patients receiving open label AIT get the benefit of the active and placebo components but it can be difficult to say how much benefit is due to the active component. The use of active placebos has been proposed but brings its own problems (ethical and scientific). An EAACI Task Force has been established to address these issues. Here we review the current literature on the placebo effect in general, with a special focus on AIT trials, and indicate what we believe to be important considerations and unmet needs in AIT trial design.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
European Academy of Allergy and Clinical Immunology
Quality of life
Synthetic peptide immunoregulatory epitopes
Benedetti F, Carlino E, Pollo A. How placebos change the patient's brain. Neuropsychopharmacology 2011;36:339–54
del Cuvillo A, Sastre J, Bartra J, Mullol J, DaVila I, Montoro J, et al. Placebo effect in clinical trials involving patients with allergic rhinitis. J Investig Allergol Clin Immunol 2011;21(Suppl 3):40–5
Wedi B, Wieczorek D, Kapp A. Placebo effect in clinical trials with allergen-specific immunotherapy with inhalant allergens. Hautarzt. 2017;68:297–306
Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M. The placebo effect in allergen-specific immunotherapy trials. Clin Transl Allergy 2013;3:42
The European Agency for the Evaluation of Medicinal Products (EMA). ICH E 9: note for guidance on statistical principles for clinical trials (CPMP/ICH/363/96). 1998
Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy 2014;69:854–67
Freeman J. Lancet 1914;2:814
Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component Lancet. 1954;266:1055–7
Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med 1965;273:675–9
Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434–40
Pfaar O, Bonini S, Cardona V, Demoly P, Jakob T, Jutel M, et al. Perspectives in allergen immunotherapy: 2017 and beyond. Allergy 2018;73(Suppl 104):5–23
Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by anti-allergic drugs. Br Med J 1991;302:265–9
Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Clinical efficacy and safety of specific allergy vaccination with Alutard Grass in seasonal allergic rhinoconjunctivitis: a large-scale randomised double-blind placebo-controlled multi-centre study (UKIS—The UK Immunotherapy Study). J Allergy Clin Immunol 2006;117:319–25
La Rosa M, Ranno C, André C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425–32
Varney VA, Edwards J, Mavroleon G, Brewster H, Tabbah K, Frew AJ. Clinical effects of desensitisation to cat dander: a double blind placebo-controlled trial. Clin Exp Allergy 1997;27:860–7
Circassia Pharmaceuticals Inc. Circassia announces top-line results from cat allergy phase III study. 2016. https://www.circassia.com/media/press-releases/circassia-announces-top-line-results-from-cat-allergy-phase-iii-study Accessed 10 March 2018
Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larché M, et al. Fel d 1—derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013;131:103–9
Pfaar O, Alvaro M, Cardona V, Hamelmann E, Moesges R, Kleine-Tebbe J. Clinical trials in allergen immunotherapy: current concepts and future needs. Allergy. 2018; https://doi.org/10.1111/all.13429
Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:4–12
Frew AJ, Smith HE. Sublingual immunotherapy. J Allergy Clin Immunol. 2001;107:441–4
Smith HE, White PJ, Annila I, Poole J, Andre C, Frew AJ. Randomised controlled trial of high dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004;114:831–7
Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317–24
Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009;39:1786–800
*This article is based on a lecture given by the corresponding author at the 15th International Paul Ehrlich Seminar (September 6–9, 2017), Bad Homburg, Germany.
Conflict of interest
A.J. Frew has conducted clinical trials of subcutaneous and sublingual immunotherapy with several pharmaceutical companies including ALK-Abello, Allergopharma and Stallergenes but has no other current interests to report. O. Pfaar reports grants and personal fees from ALK-Abelló, grants and personal fees from Allergopharma, grants and personal fees from Stallergenes Greer, grants and personal fees from HAL Allergy Holding B.V./HAL Allergie GmbH, grants and personal fees from Bencard Allergie GmbH/Allergy Therapeutics, grants and personal fees from Lofarma, grants from Biomay, grants from Nuvo, grants from Circassia, grants and personal fees from Biotech Tools S.A., grants and personal fees from Laboratorios LETI/LETI Pharma, personal fees from Novartis Pharma, personal fees from MEDA Pharma, grants and personal fees from Anergis S.A., personal fees from Mobile Chamber Experts (a GA2LEN Partner), personal fees from Pohl-Boskamp, personal fees from Indoor Biotechnologies, grants from Glaxo Smith Kline, outside the submitted work.
Cite this as
Frew AJ, Pfaar O. Placebo effects in allergen immunotherapy: an experts’ opinion. Allergo J Int 2018;27:162–6
About this article
Cite this article
Frew, A.J., Pfaar, O. Placebo effects in allergen immunotherapy: an experts’ opinion. Allergo J 27, 31–35 (2018). https://doi.org/10.1007/s15007-018-1689-5
- clinical trials
- EAACI task force